Lilly launches Employer Connect platform with Zepbound KwikPen priced at $449
Lilly's new platform lets employers build their own obesity drug coverage, but whether a patient pays less depends on decisions their employer makes.
Eli Lilly launched a platform called Employer Connect on March 5, 2026, that pairs employers with more than fifteen independent program administrators to build obesity treatment coverage for their workers [1]. Under the program, Lilly sells the Zepbound (tirzepatide) KwikPen to network pharmacies at a discounted price of $449 for all doses [1].
Lilly said the platform is meant to close a coverage gap. Obesity affects more than 100 million American adults and costs the U.S. economy more than $1.7 trillion a year, the company said, including $480 billion in direct medical costs and $1.24 trillion in lost productivity [1]. Coverage for obesity management medicines remains inconsistent across employer-sponsored plans, leaving roughly half of commercially insured employees without covered access, according to Lilly [1].
"For far too many people living with obesity, starting or staying on treatment isn't just a medical decision, it's an access decision driven by coverage and cost," said Ilya Yuffa, executive vice president and president of Lilly USA and Global Customer Capabilities [1]. He said the program connects employers to a range of independent administrators and cost-sharing options so "their employees can access prescribed treatment at reduced out-of-pocket costs" [1].
Administrators listed at launch include 9amHealth, Andel, Calibrate Health, Crux Health, eMed, FlyteHealth, Form Health, Goodpath, GoodRx, Ilant Health, Mark Cuban Cost Plus Drug Company, Onsera Health, ReviveHealth, SALTA Direct Primary Care, Sesame, Teladoc Health, Transcarent and Waltz Health [1]. Lilly said the program includes nationwide pharmacy support through a dedicated network, including the dispensing pharmacies HealthDyne and CenterWell [1].
Lilly said the $449 figure is the discounted price it charges network pharmacies, not a patient copay. The final cost to an employer "may vary based on their choice of pharmacy and program administrator," and what an employee pays will vary based on the cost-share model an employer chooses and the dispensing and service fees agreed to with the independent program administrators, the company said [1].
Kevin Hern, senior vice president of Lilly Employer, said the approach enables coverage outside traditional benefit designs and "can help employees access authentic obesity management medicines with more affordable out-of-pocket costs" [1].
Zepbound was the most prescribed weight management medication in 2025, according to Lilly [1]. The Food and Drug Administration recently approved the single-patient-use KwikPen, which delivers four weekly injections from a single device [1]. In the SURMOUNT-1 trial, adults taking Zepbound 15 mg lost an average of 20.9% of their body weight over 72 weeks, compared with 3.1% for placebo, the company said [1]. In SURMOUNT-5, people taking Zepbound lost an average of 50 pounds (20.2%) versus 33 pounds (13.7%) for injectable Wegovy (semaglutide) [1]. Lilly notes that SURMOUNT-5 was an open-label study, so the data are less rigorous and the findings less certain [1].
Why it matters for patients
Whether a weight-management prescription is covered is usually decided by an employer, not by a doctor or a pharmacy counter. Employer Connect is aimed at that decision. An employer has to choose to take part, choose an administrator, and choose how much of the cost to share with employees [1].
The $449 price is what Lilly charges network pharmacies, not a promised patient copay. A patient's actual out-of-pocket cost under this program depends on the employer's plan design and the fees charged by the administrator and pharmacy [1]. That means two people at different companies, or even in different plans at the same company, could pay different amounts for the same medicine.
Lilly has not disclosed how many employers have signed up, how many employees could gain coverage, or what employees will pay on average. Those figures have not been reported [1].
What happens next
Lilly said it will continue to grow the number of program administrators on the platform [1]. The company did not give a date for when employers can enroll or when coverage under the program would begin, and no timeline for expansion was disclosed [1]. Employers, benefit consultants and other groups can contact Lilly at EmployerAccess@lilly.com for details [1].
Zepbound is approved for adults with obesity, or some adults who are overweight with at least one weight-related medical problem, to lose weight and keep it off, and for adults with moderate-to-severe obstructive sleep apnea and obesity [1]. Lilly states that Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines, and that it is not known whether Zepbound is safe and effective in children [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.